74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
ChromaDex Corp
Closed
Sector Healthcare
5.43 -4.4
Overview
Share price change
24h
Min
5.43
Max
5.5
Income | 1.9M 1.9M |
|---|---|
Sales | 12M 35M |
P/E Sector Avg | 292 73.394 |
EPS | 0.02 |
Profit margin | 5.378 |
Employees | 106 |
EBITDA | 1.9M 2M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +36.53 upside |
Next Earnings | 5 Mar 2025 |
|---|
Market Cap | 446M |
|---|---|
Previous open | 9.83 |
Previous close | 5.43 |
News Sentiment
By Acuity
50%
50%
157 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
ChromaDex Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
ChromaDex Corp Forecast
Price Target
By TipRanks
36.53% upside
12 Months Forecast
Average 7.4 USD 36.53%
High 8 USD
Low 6.8 USD
Based on 2 Wall Street analysts offering 12 month price targets forChromaDex Corp - Dist in the last 3 months.
Sentiment
By Acuity
157 / 393 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About ChromaDex Corp
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.
